HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 2 (2005), Issue 2 (February)

1. Characterization of a novel human anti-HIV-1 gp41 IgM monoclonal antibody designated clone 37.
   DNA Cell Biol, 23(12): 836-41. [Abstract] [Full-text]
2. GB virus C coinfection and HIV-1 disease progression: The Amsterdam Cohort Study.
   J Infect Dis, 191(5): 678-85. [Abstract] [Full-text]
3. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.
   J Infect Dis, 191(5): 666-77. [Abstract] [Full-text]
4. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.
   J Infect Dis, 191(5): 654-65. [Abstract] [Full-text]
5. Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected children.
   Pediatrics, 115(2): 380-7. [Abstract] [Full-text]
6. Gender differences in perinatal HIV acquisition among African infants.
   Pediatrics, 115(2): e167-72. [Abstract] [Full-text]
7. HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome.
   Nucleic Acids Res, 33(2): 796-804. [Abstract] [Full-text]
8. 'My fear is to fall in love again...' how HIV-positive African women survive in London.
   Soc Sci Med, 60(8): 1729-38. [Abstract] [Full-text]
9. The trans-Golgi network-associated human ubiquitin-protein ligase POSH is essential for HIV type 1 production.
   Proc Natl Acad Sci U S A, 102(5): 1478-83. [Abstract] [Full-text]
10. Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection.
    Pediatrics, 115(2): e173-82. [Abstract] [Full-text]
11. Interpersonal violence, substance use, and HIV-related behavior and cognitions: a prospective study of impoverished women in Los Angeles County.
    AIDS Behav, 8(4): 463-74. [Abstract] [Full-text]
12. The efficacy of an integrated risk reduction intervention for HIV-positive women with child sexual abuse histories.
    AIDS Behav, 8(4): 453-62. [Abstract] [Full-text]
13. Abuse in the close relationships of people with HIV.
    AIDS Behav, 8(4): 441-51. [Abstract] [Full-text]
14. Deconstructing the relationship between intimate partner violence and sexual HIV risk among drug-involved men and their female partners.
    AIDS Behav, 8(4): 429-39. [Abstract] [Full-text]
15. Adult trauma and HIV status among Latinas: effects upon psychological adjustment and substance use.
    AIDS Behav, 8(4): 417-28. [Abstract] [Full-text]
16. Ethnicity, serostatus, and psychosocial differences in sexual risk behavior among HIV-seropositive and HIV-seronegative women.
    AIDS Behav, 8(4): 405-15. [Abstract] [Full-text]
17. Predictors of unprotected anal intercourse among HIV-positive Latino gay and bisexual men.
    AIDS Behav, 8(4): 379-89. [Abstract] [Full-text]
18. Social support among HIV positive injection drug users: implications to integrated intervention for HIV positives.
    AIDS Behav, 8(4): 357-63. [Abstract] [Full-text]
19. HIV-1 clade promoters strongly influence spatial and temporal dynamics of viral replication in vivo.
    J Clin Invest, 115(2): 348-58. [Abstract] [Full-text]
20. HIV-1-specific CD4+ T lymphocyte turnover and activation increase upon viral rebound.
    J Clin Invest, 115(2): 443-50. [Abstract] [Full-text]
21. Breast cancer in women with HIV/AIDS: report of five cases with a review of the literature.
    J Surg Oncol, 89(1): 23-7. [Abstract] [Full-text]
22. Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C-infected patients from South Africa.
    J Clin Microbiol, 43(2): 857-61. [Abstract] [Full-text]
23. Sensitivity and specificity of the ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for detection of HIV-1 drug resistance mutations by use of an ABI PRISM 3100 genetic analyzer.
    J Clin Microbiol, 43(2): 813-7. [Abstract] [Full-text]
24. High-throughput screening method of inhibitors that block the interaction between 2 helical regions of HIV-1 gp41.
    J Biomol Screen, 10(1): 13-9. [Abstract] [Full-text]
25. Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response.
    Vaccine, 23(13): 1559-73. [Abstract] [Full-text]
26. Phylogenetic reconstruction of a known HIV-1 CRF04_cpx transmission network using maximum likelihood and Bayesian methods.
    J Mol Evol, 59(5): 709-17. [Abstract] [Full-text]
27. Nef-induced alteration of the early/recycling endosomal compartment correlates with enhancement of HIV-1 infectivity.
    J Biol Chem, 280(6): 5032-44. [Abstract] [Full-text]
28. Mechanistic insights into the suppression of drug resistance by human immunodeficiency virus type 1 reverse transcriptase using alpha-boranophosphate nucleoside analogs.
    J Biol Chem, 280(5): 3838-46. [Abstract] [Full-text]
29. Cooperative effects in phospholipid monolayers induced by a peptide from HIV-1 capsid protein.
    Colloids Surf B Biointerfaces, 41(1): 15-20. [Abstract] [Full-text]
30. Sam68 is absolutely required for Rev function and HIV-1 production.
    Nucleic Acids Res, 33(3): 873-9. [Abstract] [Full-text]
31. Splicing of human immunodeficiency virus RNA is position-dependent suggesting sequential removal of introns from the 5' end.
    Nucleic Acids Res, 33(3): 825-37. [Abstract] [Full-text]
32. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision.
    Proc Natl Acad Sci U S A, 102(6): 2093-8. [Abstract] [Full-text]
33. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team.
    J Clin Oncol, 23(5): 990-8. [Abstract] [Full-text]
34. The risk of cancer in HIV-infected people in southeast England: a cohort study.
    Br J Cancer, 92(1): 194-200. [Abstract] [Full-text]
35. Baseline self-perceived risk of HIV infection independently predicts the rate of HIV seroconversion in a prospective cohort of injection drug users.
    Int J Epidemiol, 34(1): 152-8. [Abstract] [Full-text]
36. Chimeric human immunodeficiency virus type 1 virions that contain the simian immunodeficiency virus nef gene are cyclosporin A resistant.
    J Virol, 79(5): 3211-6. [Abstract] [Full-text]
37. Interleukin 7 increases human immunodeficiency virus type 1 LAI-mediated Fas-induced T-cell death.
    J Virol, 79(5): 3195-9. [Abstract] [Full-text]
38. Alternative tRNA priming of human immunodeficiency virus type 1 reverse transcription explains sequence variation in the primer-binding site that has been attributed to APOBEC3G activity.
    J Virol, 79(5): 3179-81. [Abstract] [Full-text]
39. Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction.
    J Virol, 79(5): 3139-45. [Abstract] [Full-text]
40. Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN--gp120 interaction.
    J Virol, 79(5): 3009-15. [Abstract] [Full-text]
41. DNA damage sensors ATM, ATR, DNA-PKcs, and PARP-1 are dispensable for human immunodeficiency virus type 1 integration.
    J Virol, 79(5): 2973-8. [Abstract] [Full-text]
42. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys.
    J Virol, 79(5): 2956-63. [Abstract] [Full-text]
43. Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection.
    J Virol, 79(5): 2823-30. [Abstract] [Full-text]
44. Vpr protein of human immunodeficiency virus type 1 binds to 14-3-3 proteins and facilitates complex formation with Cdc25C: implications for cell cycle arrest.
    J Virol, 79(5): 2780-7. [Abstract] [Full-text]
45. Sulfonated naphthyl porphyrins as agents against HIV-1.
    J Inorg Biochem, 99(3): 813-21. [Abstract] [Full-text]
46. 6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro.
    Antiviral Res, 65(2): 117-24. [Abstract] [Full-text]
47. A novel HIV-1 antiviral high throughput screening approach for the discovery of HIV-1 inhibitors.
    Antiviral Res, 65(2): 107-16. [Abstract] [Full-text]
48. Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig)G from infected patients capture HIV-1 via antibodies directed against the principal immunodominant domain of gp41.
    Virology, 333(1): 102-13. [Abstract] [Full-text]
49. Epstein-Barr virus associated with primary CNS lymphoma and disseminated BCG infection in a child with AIDS.
    Int J Infect Dis, 9(2): 96-103. [Abstract] [Full-text]
50. Positional effects of the central DNA flap in HIV-1-derived lentiviral vectors.
    Biochem Biophys Res Commun, 328(4): 987-94. [Abstract] [Full-text]
51. Current guidelines for the management of UK Infants born to HIV-1 infected mothers.
    Early Hum Dev, 81(1): 103-10. [Abstract] [Full-text]
52. Cognitive coping intervention for acutely ill HIV-positive men.
    J Clin Nurs, 14(3): 321-6. [Abstract] [Full-text]
53. Sexual risk behaviour of Canadian participants in the first efficacy trial of a preventive HIV-1 vaccine.
    CMAJ, 172(4): 479-83. [Abstract] [Full-text]
54. Cooperative interaction of C/EBP beta and Tat modulates MCP-1 gene transcription in astrocytes.
    J Neuroimmunol, 160(1): 219-27. [Abstract] [Full-text]
55. The HIV-1 coat protein gp120 regulates CXCR4-mediated signaling in neural progenitor cells.
    J Neuroimmunol, 160(1): 68-76. [Abstract] [Full-text]
56. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.
    JAMA, 293(7): 817-29. [Abstract] [Full-text]
57. Displacement of SATB1-bound histone deacetylase 1 corepressor by the human immunodeficiency virus type 1 transactivator induces expression of interleukin-2 and its receptor in T cells.
    Mol Cell Biol, 25(5): 1620-33. [Abstract] [Full-text]
58. Stability of HCV, HIV-1 and HBV nucleic acids in plasma samples under long-term storage.
    Biologicals, 33(1): 9-16. [Abstract] [Full-text]
59. HIV seropositive in pregnant South African women who initially refuse routine antenatal HIV screening.
    BJOG, 112(3): 370-1. [Abstract] [Full-text]
60. A statistical characterization of consistent patterns of human immunodeficiency virus evolution within infected patients.
    Mol Biol Evol, 22(3): 456-68. [Abstract] [Full-text]
61. HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia.
    J Infect Dis, 191(6): 890-8. [Abstract] [Full-text]
62. Sex-based differences in T lymphocyte responses in HIV-1-seropositive individuals.
    J Infect Dis, 191(6): 881-5. [Abstract] [Full-text]
63. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection.
    J Infect Dis, 191(6): 866-72. [Abstract] [Full-text]
64. The process of disclosing HIV serostatus between HIV-positive mothers and their HIV-negative children.
    AIDS Patient Care STDS, 19(2): 100-9. [Abstract] [Full-text]
65. Novel [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2" -dioxide) derivatives with anti-HIV-1 and anti-human-cytomegalovirus activity.
    J Med Chem, 48(4): 1158-68. [Abstract] [Full-text]
66. Activation of protein phosphatase-2A1 by HIV-1 Vpr cell death causing peptide in intact CD(4+) T cells and in vitro.
    J Cell Biochem, 94(4): 816-25. [Abstract] [Full-text]
67. Profile of patients with Kaposi's sarcoma in the era of highly active antiretroviral therapy.
    J Clin Oncol, 23(6): 1253-60. [Abstract] [Full-text]
68. HIV-1 integrase crosslinked oligomers are active in vitro.
    Nucleic Acids Res, 33(3): 977-86. [Abstract] [Full-text]
69. Treatments of AIDS-related Kaposi's sarcoma.
    Crit Rev Oncol Hematol, 53(3): 253-65. [Abstract] [Full-text]
70. Nef expressed from human immunodeficiency virus type 1 extrachromosomal DNA downregulates CD4 on primary CD4+ T lymphocytes: implications for integrase inhibitors.
    J Gen Virol, 86: 765-71. [Abstract] [Full-text]
71. Expressing engineered thymidylate kinase variants in human cells to improve AZT phosphorylation and human immunodeficiency virus inhibition.
    J Gen Virol, 86: 757-64. [Abstract] [Full-text]
72. Regulation of human immunodeficiency virus 1 transcription by nef microRNA.
    J Gen Virol, 86: 751-5. [Abstract] [Full-text]
73. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides.
    Adv Drug Deliv Rev, 57(4): 637-51. [Abstract] [Full-text]
74. Intracellular targeting of polymer-bound drugs for cancer chemotherapy.
    Adv Drug Deliv Rev, 57(4): 609-36. [Abstract] [Full-text]
75. Transcellular protein transduction using the Tat protein of HIV-1.
    Adv Drug Deliv Rev, 57(4): 597-608. [Abstract] [Full-text]
76. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer.
    Adv Drug Deliv Rev, 57(4): 579-96. [Abstract] [Full-text]
77. Tat peptide-mediated cellular delivery: back to basics.
    Adv Drug Deliv Rev, 57(4): 559-77. [Abstract] [Full-text]
78. Membrane-permeable arginine-rich peptides and the translocation mechanisms.
    Adv Drug Deliv Rev, 57(4): 547-58. [Abstract] [Full-text]
79. Natural resistance-associated mutations to Enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients.
    J Clin Virol, 32(3): 248-53. [Abstract] [Full-text]
80. Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.
    J Clin Virol, 32(3): 241-4. [Abstract] [Full-text]
81. Lymphoid tissue targeting of anti-HIV drugs using liposomes.
    Methods Enzymol, 391: 330-51. [Abstract] [Full-text]
82. Complementary function of the two catalytic domains of APOBEC3G.
    Virology, 333(2): 374-86. [Abstract] [Full-text]
83. T20-insensitive HIV-1 from naive patients exhibits high viral fitness in a novel dual-color competition assay on primary cells.
    Virology, 333(2): 251-62. [Abstract] [Full-text]
84. Sepharose-bound, highly sulfated glycosaminoglycans can capture HIV-1 from culture medium.
    Carbohydr Res, 340(4): 759-64. [Abstract] [Full-text]
85. HIV-1-associated uracil DNA glycosylase activity controls dUTP misincorporation in viral DNA and is essential to the HIV-1 life cycle.
    Mol Cell, 17(4): 479-90. [Abstract] [Full-text]
86. Anthropometry of fetal growth in rural Malawi in relation to maternal malaria and HIV status.
    Arch Dis Child Fetal Neonatal Ed, 90(2): F161-5. [Abstract] [Full-text]
87. Heterosexual behavioral maintenance and change following HIV counseling and testing.
    J Health Psychol, 10(2): 287-300. [Abstract] [Full-text]
88. Decreased depression up to one year following CBSM+ intervention in depressed women with AIDS: the smart/EST women's project.
    J Health Psychol, 10(2): 223-31. [Abstract] [Full-text]
89. Hexitol nucleic acid-containing aptamers are efficient ligands of HIV-1 TAR RNA.
    Biochemistry, 44(8): 2926-33. [Abstract] [Full-text]
90. HIV-1 subtypes and circulating recombinant forms (CRFs) from HIV-infected patients residing in two regions of central and southern Italy.
    J Med Virol, 75(4): 483-90. [Abstract] [Full-text]
91. Circulation of novel HIV type 1 A, B/C, and F subtypes in Argentina.
    AIDS Res Hum Retroviruses, 21(2): 158-64. [Abstract] [Full-text]
92. Subtype B and subtype C HIV type 1 recombinants in the northeastern state of Manipur, India.
    AIDS Res Hum Retroviruses, 21(2): 152-7. [Abstract] [Full-text]
93. Analysis of full-length human immunodeficiency virus type 1 genome reveals a variable spectrum of subtypes B and f recombinants in São Paulo, Brazil.
    AIDS Res Hum Retroviruses, 21(2): 145-51. [Abstract] [Full-text]
94. Studies in macaques on cross-clade T cell responses elicited by a DNA/MVA AIDS vaccine, better conservation of CD8 than CD4 T cell responses.
    AIDS Res Hum Retroviruses, 21(2): 140-4. [Abstract] [Full-text]
95. Identification of granulocyte-macrophage colony-stimulating factor and lipopolysaccharide-induced signal transduction pathways that synergize to stimulate HIV type 1 production by monocytes from HIV type 1 transgenic mice.
    AIDS Res Hum Retroviruses, 21(2): 125-39. [Abstract] [Full-text]
96. Association of CCR5 human haplogroup E with rapid HIV type 1 disease progression.
    AIDS Res Hum Retroviruses, 21(2): 111-5. [Abstract] [Full-text]
97. Seronegative secondary syphilis in an HIV-infected patient.
    Clin Exp Dermatol, 30(2): 158-9. [Abstract] [Full-text]
98. Analysis of HIV- type 1 protease and reverse transcriptase in Brazilian children failing highly active antiretroviral therapy (HAART).
    Rev Inst Med Trop Sao Paulo, 47(1): 1-5. [Abstract] [Full-text]
99. In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase.
    Antimicrob Agents Chemother, 49(3): 1139-44. [Abstract] [Full-text]
100. Gene transfer to repopulating human CD34+ cells using amphotropic-, GALV-, or RD114-pseudotyped HIV-1-based vectors from stable producer cells.
     Mol Ther, 11(3): 452-9. [Abstract] [Full-text]
101. Improving the safety of a conditional-live human immunodeficiency virus type 1 vaccine by controlling both gene expression and cell entry.
     J Virol, 79(6): 3855-8. [Abstract] [Full-text]
102. Enhanced cellular immunity in macaques following a novel peptide immunotherapy.
     J Virol, 79(6): 3748-57. [Abstract] [Full-text]
103. Immunologic pressure within class I-restricted cognate human immunodeficiency virus epitopes during highly active antiretroviral therapy.
     J Virol, 79(6): 3653-63. [Abstract] [Full-text]
104. Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production.
     J Virol, 79(6): 3627-38. [Abstract] [Full-text]
105. Importin-alpha promotes passage through the nuclear pore complex of human immunodeficiency virus type 1 Vpr.
     J Virol, 79(6): 3557-64. [Abstract] [Full-text]
106. Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.
     J Virol, 79(6): 3536-43. [Abstract] [Full-text]
107. Stoichiometry of antibody neutralization of human immunodeficiency virus type 1.
     J Virol, 79(6): 3500-8. [Abstract] [Full-text]
108. A noninfectious simian/human immunodeficiency virus DNA vaccine that protects macaques against AIDS.
     J Virol, 79(6): 3419-28. [Abstract] [Full-text]
109. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.
     J Virol, 79(6): 3358-69. [Abstract] [Full-text]
110. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
     J Virol, 79(6): 3329-38. [Abstract] [Full-text]
111. Signature for long-term vaccine-mediated control of a Simian and human immunodeficiency virus 89.6P challenge: stable low-breadth and low-frequency T-cell response capable of coproducing gamma interferon and interleukin-2.
     J Virol, 79(6): 3243-53. [Abstract] [Full-text]
112. Assessing the health status of young AIDS and other orphans in Kampala, Uganda.
     Trop Med Int Health, 10(3): 210-5. [Abstract] [Full-text]
113. Human immunodeficiency virus (HIV)-2-specific T lymphocyte proliferative responses in HIV-2-infected and in HIV-2-exposed but uninfected individuals in Guinea-Bissau.
     Clin Exp Immunol, 139(3): 483-9. [Abstract] [Full-text]
114. Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques.
     Vaccine, 23(16): 1949-56. [Abstract] [Full-text]
115. Plant based HIV-1 vaccine candidate: Tat protein produced in spinach.
     Vaccine, 23(15): 1875-80. [Abstract] [Full-text]
116. Objective analysis of retinal damage in HIV-positive patients in the HAART era using OCT.
     Am J Ophthalmol, 139(2): 295-301. [Abstract] [Full-text]
117. The fidelity of DNA synthesis by human immunodeficiency virus type 1 reverse transcriptase increases in the presence of polyamines.
     FEBS Lett, 579(6): 1435-40. [Abstract] [Full-text]
118. HIV/AIDS symptom management in Southern Africa.
     J Pain Symptom Manage, 29(2): 185-92. [Abstract] [Full-text]
119. Predictors and Correlates of Fatigue in HIV/AIDS.
     J Pain Symptom Manage, 29(2): 173-84. [Abstract] [Full-text]
120. CD4 down-regulation by HIV-1 and simian immunodeficiency virus (SIV) Nef proteins involves both internalization and intracellular retention mechanisms.
     J Biol Chem, 280(9): 7413-26. [Abstract] [Full-text]
121. RNase S complex bearing arginine-rich peptide and anti-HIV activity.
     J Mol Recognit, 18(2): 169-74. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.